Drug use Reconsidered in the Elderly using goal Attainment scales during Medication Review - The DREAMeR-study

Drug use Reconsidered in the Elderly using goal Attainment scales during Medication Review - The DREAMeR-study - The DREAMeR-study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON44034

Enrollment

750

Registered

2016-03-22

Start date

2016-04-18

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

alle aandoeningen waarbij farmacotherapie wordt ingezet n.a.

Interventions

Patients in the intervention group will directly receive a clinical medication review at the start of the study. Patients in the waiting list group will receive usual care and will be provided with

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Home-dwelling patients aged 70 years or older, using 7 or more chronic medicines

Exclusion criteria

Exclusion criteria: Persons receiving repeat prescriptions solely from a specialist. (the GP is not the primary caregiver) Persons with a life expectancy shorter than 6 months. Persons who had a hospital admission

Design outcomes

Primary

Measure	Time frame
1. Health-related quality of life (EQ-5D-5L) 2. Number of hindering complaints per patient	—

Secondary

Measure	Time frame
1. Health care utilization (used for calculating direct medical costs and non-medical costs) 2. The number of drug changes per patient 3. The number and type of ceased drugs after 3 and 6 months 4. The number and type of added drugs after 3 and 6 months 5. The number and type of goals at baseline 6. Scores on the Goal Attainment Scales (GAS) measured after 3 and 6 months 7. The number and type of drug-related problems (DRPs) per patient 8. Implementation rate of the recommendations associated with the DRPs	—

Measure

Time frame

1. Health care utilization (used for calculating direct medical costs and non-medical costs) 2. The number of drug changes per patient 3. The number and type of ceased drugs after 3 and 6 months 4. The number and type of added drugs after 3 and 6 months 5. The number and type of goals at baseline 6. Scores on the Goal Attainment Scales (GAS) measured after 3 and 6 months 7. The number and type of drug-related problems (DRPs) per patient 8. Implementation rate of the recommendations associated with the DRPs

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)